Home / Business and Economy / Kenanga Launches First Hang Seng Biotech Warrants
Kenanga Launches First Hang Seng Biotech Warrants
10 Sep
Summary
- New warrants offer Malaysian investors access to Hong Kong's biotech sector.
- The Hang Seng Biotech Index surged 64.5% in 2025, outpacing major indices.
- This launch marks a significant innovation in structured products.
Kenanga Investment Bank Berhad has introduced the world's first structured warrants linked to the Hang Seng Biotech Index (HSBIO), branded as NagaWarrants by Kenanga. These new offerings, HSBIO-CAA and HSBIO-HBA, are designed to provide Malaysian investors with access to Hong Kong's rapidly expanding biotechnology and healthcare sector. This sector is identified as a significant long-term growth theme, propelled by demographic changes, increased healthcare demand, and ongoing medical advancements.
The launch, which occurred at the 11 Belt and Road Summit in Hong Kong on September 9, 2026, signifies a major step in structured product innovation. The HSBIO index, comprising 30 of the largest biotech and healthcare companies listed in Hong Kong, demonstrated strong performance in 2025, achieving a 64.5% gain. This growth underscores the rising investor enthusiasm for China's biotechnology landscape.
Datuk Chay Wai Leong, Group Managing Director of Kenanga Investment Bank Berhad, emphasized the Group's commitment to product innovation and providing accessible investment solutions for global market trends. Philip Lim Kuok Wei, Head of Equity Markets, highlighted the growing investor interest in targeted exposures, particularly in the dynamic biotechnology sector, and noted that these warrants offer a familiar way to engage with this theme.
The introduction of these warrants expands NagaWarrants' portfolio, which already includes products linked to the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng TECH Index. Kenanga Group's efforts in product innovation have been recognized with the Best Warrants Issuer Malaysia 2026 award.
